EGFR is known as epidermal growth factor receptor, proto-oncogene c-ErbB-1 , receptor tyrosine-protein kinase erbB-1.  It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  The human EGFR has 1210 amino acid (aa), including a 24 aa signal peptide, a 621 aa ECD, and a 23 aa TM segment. It shares 88% aa sequence identity with murine EGFR and 43-44% identity with the ECD of other 3 human EGFR members.  EGFR binds to a subset of the EGF family ligands, including EGF, amphiregulin, TGFα, β-cellulin, epiregulin, HB-EGF, and epigen.  EGFR signaling is initiated by ligand binding, leading to EGFR receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain and receptor activation.  Subsequently, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  EGFR is known to form heterodimers with the ligand-activated HER3 or HER4.  EGFR is overexpressed in a variety of tumors.  Mutations in EGFR gene are associated with lung cancer.  EGFR is the target of several anti-cancer therapeutics. The purified recombinant anti-EGFR monoclonal antibody binds human EGFR with high affinity, neutralizes EGFR signaling activity and inhibits the growth of EGFR-expressing tumor cells.

EGFR is known as epidermal growth factor receptor, proto-oncogene c-ErbB-1 , receptor tyrosine-protein kinase erbB-1.  It is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTK).  Four members of the EGFR family have been identified: EGFR (ERBB1, HER1), HER2 (ERBB2), HER3 (ERBB3) and HER4 (ERBB4).  They typically contain an extracellular ligand binding domain (ECD), a transmembrane domain (TM), and an intracellular kinase domain that can interact with a multitude of signaling molecules and exhibit both ligand-dependent and ligand-independent activity.  The human EGFR has 1210 amino acid (aa), including a 24 aa signal peptide, a 621 aa ECD, and a 23 aa TM segment. It shares 88% aa sequence identity with murine EGFR and 43-44% identity with the ECD of other 3 human EGFR members.  EGFR binds to a subset of the EGF family ligands, including EGF, amphiregulin, TGFα, β-cellulin, epiregulin, HB-EGF, and epigen.  EGFR signaling is initiated by ligand binding, leading to EGFR receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain and receptor activation.  Subsequently, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.  EGFR is known to form heterodimers with the ligand-activated HER3 or HER4.  EGFR is overexpressed in a variety of tumors.  Mutations in EGFR gene are associated with lung cancer.  EGFR is the target of several anti-cancer therapeutics. The purified recombinant anti-EGFR monoclonal antibody binds human EGFR with high affinity, neutralizes EGFR signaling activity and inhibits the growth of EGFR-expressing tumor cells.

 

Product Details

 

Gene Symbol: EGFR; ERBB; ERBB1; HER1; mENA; PIG61; SA7

 

NCBI Gene ID: 1956 (human)

 

Uniprot Entry: P00533 (human)

 

Construct Details: Expressed as a single-chain Fv (scFv) from anti-EGFR VH and VL region fused with a scFv of anti-CD3e VH and VL region with a His-tag at the C-terminus. Exists as a monomer under non-reducing and reducing condition.

  

Source:  Mammalian cells stably expressing anti-EGFR:anti-CD3e  bispecific antibody (in a scFv-scFv’ format) and growing in chemical-defined media with no animal component or antibiotics

 

M.W.: Calculated molecular mass (kDa): 54.6; Estimated by SDS-PAGE under reducing condition(kDa): 55-60

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image inserted).

 

Formulation: Supplied at 0.5 mg/ml in sterile PBSpH7.4 (carrier and preservative free). The purified recombinant antibody was labeled with Biotin (3-5 Biotin per IgG) using the standard procedure.

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds EGFR extracellular domain (SKU#FCL0169; FCL0083) with high affinity and recognizes CD3e in the context of TCR complex on T cells.  Potently promotes T cell-mediated anti-tumor cytotoxicity after engaging with tumor cell surface antigen EGFR

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

 

Technical Data

 

Recombinant EGFR ECD protein (SKU#FCL0169) was immobilized at 20 ng/well on a 96-well ELISA plate and incubated with serially diluted anti-EGFR human IgG1 monoclonal antibody (SKU#MAB0118). Anti-HER2 (SKU#MAB0203) human IgG1 monoclonal antibody was used as a control to demonstrate the specificity of EGFR binding under the experimental conditions.  The bound antibodies were detected by goat anti-human IgG HRP-conjugated secondary antibody.  The ELISA binding curve was fit and K_D was calculated for anti-EGFR : EGFR binding (affinity/avidity) to be 13 ± 0.7 pM. 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1.  Science 306: 1506-1507, 2004.
2.  Nature 309: 418-425, 1984
3.  New Eng. J. Med. 350: 2129-2139, 2004.
4.  Cell 125: 1137-1149, 2006.

 

 

 

Additional supporting documents, including PDS, COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.